| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A potential novel cancer immunotherapy: Agonistic anti-CD40 antibodies
|
Jian, Cheng-Zhe
|
|
|
29 |
3 |
p.
|
artikel
|
| 2 |
Artificial intelligence in drug discovery: A new frontier in the fight against Mycobacterium tuberculosis
|
Abavisani, Mohammad
|
|
|
29 |
3 |
p.
|
artikel
|
| 3 |
Can drug production be democratized?
|
D'Urso, Gennaro
|
|
|
29 |
3 |
p.
|
artikel
|
| 4 |
Communicating computational workflows in a regulatory environment
|
Keeney, Jonathon G.
|
|
|
29 |
3 |
p.
|
artikel
|
| 5 |
Cost-effectiveness comparison between blood biomarkers and conventional tests in Alzheimer's disease diagnosis
|
Noda, Kenta
|
|
|
29 |
3 |
p.
|
artikel
|
| 6 |
Druggable genome special issue: An introduction
|
Sharma, Karlie R.
|
|
|
29 |
3 |
p.
|
artikel
|
| 7 |
Drugging the entire human proteome: Are we there yet?
|
Smith, Micholas Dean
|
|
|
29 |
3 |
p.
|
artikel
|
| 8 |
Gen AI’s real opportunity in drug development? As a smart, strategic decision aid
|
Jamieson, Daniel
|
|
|
29 |
3 |
p.
|
artikel
|
| 9 |
Illuminating function of the understudied druggable kinome
|
Gomez, Shawn M.
|
|
|
29 |
3 |
p.
|
artikel
|
| 10 |
Illuminating the druggable genome: Pathways to progress
|
Sharma, Karlie R.
|
|
|
29 |
3 |
p.
|
artikel
|
| 11 |
Illuminating the understudied GPCR-ome
|
Majumdar, Sreeparna
|
|
|
29 |
3 |
p.
|
artikel
|
| 12 |
Informatic challenges and advances in illuminating the druggable proteome
|
Taujale, Rahil
|
|
|
29 |
3 |
p.
|
artikel
|
| 13 |
Innovative strategies for measuring kinase activity to accelerate the next wave of novel kinase inhibitors
|
Veth, Tim S.
|
|
|
29 |
3 |
p.
|
artikel
|
| 14 |
NAFLD and NASH: etiology, targets and emerging therapies
|
Wei, Shulin
|
|
|
29 |
3 |
p.
|
artikel
|
| 15 |
Nanocrystal technologies in biomedical science: From the bench to the clinic
|
Pardhi, Ekta
|
|
|
29 |
3 |
p.
|
artikel
|
| 16 |
Nanoformulations of chemotherapeutic activators of the cGAS–STING pathway in tumor chemoimmunotherapy
|
Wang, Lingzhi
|
|
|
29 |
3 |
p.
|
artikel
|
| 17 |
Nanomedicines as enhancers of tumor immunogenicity to augment cancer immunotherapy
|
Dogheim, Gaidaa M.
|
|
|
29 |
3 |
p.
|
artikel
|
| 18 |
Overview of the Knowledge Management Center for Illuminating the Druggable Genome
|
Oprea, Tudor I.
|
|
|
29 |
3 |
p.
|
artikel
|
| 19 |
Recent advances in bioaffinity strategies for preclinical and clinical drug discovery: Screening natural products, small molecules and antibodies
|
Jin, Haochun
|
|
|
29 |
3 |
p.
|
artikel
|
| 20 |
Recent advances in multitarget-directed ligands via in silico drug discovery
|
Maddeboina, Krishnaiah
|
|
|
29 |
3 |
p.
|
artikel
|
| 21 |
Recently reported cell migration inhibitors: Opportunities and challenges for antimetastatic agents
|
Akompong, Samuel K.
|
|
|
29 |
3 |
p.
|
artikel
|
| 22 |
Revolutionizing viral disease treatment: Phase separation and lysosome/exosome targeting as new areas and new paradigms for antiviral drug research
|
Du, Shaoqing
|
|
|
29 |
3 |
p.
|
artikel
|
| 23 |
Spatial transcriptomics data and analytical methods: An updated perspective
|
Danishuddin,
|
|
|
29 |
3 |
p.
|
artikel
|
| 24 |
Structural–functional analysis of drug target aspartate semialdehyde dehydrogenase
|
Kumar, Rajender
|
|
|
29 |
3 |
p.
|
artikel
|
| 25 |
Summary and future of medicine for hereditary angioedema
|
Ding, Lei
|
|
|
29 |
3 |
p.
|
artikel
|
| 26 |
The European Lead Factory: Results from a decade of collaborative, public–private, drug discovery programs
|
van Vlijmen, Herman
|
|
|
29 |
3 |
p.
|
artikel
|
Tijdschrift beschrijving